Latest news, research updates, and educational content from ARG Peptides
The scientific community has been closely following the development of GLP-1 receptor agonists, with semaglutide and tirzepatide emerging as two of the most studied compounds...
Read More
If you’ve been following metabolic research, you’ve likely noticed two compounds generating significant scientific interest: tirzepatide and retatrutide. Both represent advances in incretin-based peptide research,...
Read More
In the evolving landscape of peptide research, ARA-290 has emerged as a compound of significant scientific interest. Unlike many peptides that target metabolic or hormonal...
Read More
If you’ve been following the scientific literature on metabolic research, you’ve probably noticed a lot of excitement around a peptide called cagrilintide. While GLP-1 compounds...
Read More
We have some exciting news to share with our valued customers and research partners! ARG Peptides is rolling out a fresh new look for our...
Read MoreIf you’ve been following the latest in peptide research, you’ve probably heard about MOTS-c. This tiny peptide—just 16 amino acids long—has been making waves in...
Read More
If you’ve been paying attention to the world of longevity and anti-aging research, you’ve probably heard the term “NAD+” thrown around quite a bit. But...
Read More
Glucagon-like peptide-1 (GLP-1) receptor agonists have become one of the most intensively studied classes of peptides in modern biomedical research. Originally investigated for their role...
Read More
BPC-157, or Body Protection Compound-157, has emerged as one of the most extensively studied peptides in modern biomedical research. This pentadecapeptide, originally isolated from human...
Read More
At ARG Peptides, we believe in building lasting relationships with the research community. That is why we are thrilled to announce the launch of our...
Read More